Skip to main content

RxNews®

Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.

Empaveli® (pegcetacoplan) – New indication

July 28, 2025 - Apellis announced the FDA approval of Empaveli (pegcetacoplan), for the treatment of adult and pediatric patients aged 12 years and older with C3 glomerulopathy (C3G) or primary immune-complex membranoproliferative glomerulonephritis (IC-MPGN), to reduce proteinuria.

Download PDF

Rx navigation